AQST Aquestive Therapeutics, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1398733 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY12.5%
TTM net income YoY-14.9%
TTM EPS YoY7.1%
Revenue 3-yr CAGR0.5%
Net income 3-yr CAGR—
Margins
Gross margin65.3%
Operating margin-114.1%
Net margin-162.3%
FCF margin-83.3%
EBITDA margin-113.0%
Returns
ROE—
ROA-56.0%
ROIC (approx.)—
Asset turnover0.35x
Leverage & solvency
Liabilities / assets159.4%
Debt / equity—
Current ratio6.12x
Interest coverage-5.39x
Cash quality & payout
Operating cash flow / net income0.50x
Accruals ratio-27.9%
Payout ratio—
Capex / revenue1.9%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $44.55M | $57.56M | $50.58M | $47.68M | $50.83M |
| Cost of revenue | $18.55M | $17.87M | $20.83M | $19.39M | — |
| Gross profit | $25.99M | $39.69M | $29.75M | $28.29M | — |
| R&D expense | $17.19M | $20.28M | $13.10M | $17.48M | $17.05M |
| SG&A expense | $79.85M | $50.18M | $31.75M | $52.88M | $53.48M |
| Operating income | -$71.05M | -$30.77M | -$15.10M | -$42.07M | -$34.68M |
| Interest expense | $11.12M | $11.12M | $6.34M | $6.55M | $10.05M |
| Pretax income | -$83.78M | -$44.15M | -$7.62M | -$54.41M | -$70.54M |
| Income tax | $0 | -$14,000 | $245,000 | $0 | $0 |
| Net income | -$83.78M | -$44.14M | -$7.87M | -$54.41M | -$70.54M |
| EBITDA | -$70.50M | -$30.05M | -$13.76M | -$39.68M | -$31.71M |
| EPS (basic) | -0.78 | -0.51 | -0.13 | -1.12 | -1.85 |
| EPS (diluted) | -0.78 | -0.51 | -0.13 | -1.12 | -1.85 |
| Weighted avg. shares (diluted) | 106.93M | 86.73M | 61.26M | 48.73M | 38.08M |
| Balance sheet | |||||
| Cash & equivalents | $121.17M | $71.55M | $23.87M | $27.27M | $28.02M |
| Receivables | $17.76M | $7.34M | $8.47M | — | — |
| Inventory | $6.17M | $6.04M | $6.77M | $5.78M | $4.04M |
| Current assets | $149.27M | $88.22M | $40.97M | $39.89M | $47.26M |
| PP&E, net | $3.89M | $3.80M | $4.18M | $4.08M | $5.05M |
| Intangibles | $0 | $0 | $1.28M | $1.44M | $51,000 |
| Total assets | $160.43M | $101.42M | $57.42M | $57.07M | $61.99M |
| Current liabilities | $47.61M | $18.86M | $18.31M | $39.53M | $21.96M |
| Short-term debt | $9.99M | — | — | — | — |
| Long-term debt | $27.52M | $32.50M | $27.51M | $33.45M | — |
| Total debt | $37.51M | $32.50M | $27.51M | $33.45M | — |
| Total liabilities | $194.09M | $161.58M | $163.91M | $175.62M | $144.13M |
| Shareholders' equity | -$33.66M | -$60.16M | -$106.49M | -$118.55M | -$82.13M |
| Net debt | -$83.66M | -$39.05M | $3.64M | $6.17M | — |
| Shares outstanding | 122.04M | 91.41M | 68.53M | 54.83M | 41.23M |
| Cash flow statement | |||||
| Operating cash flow | -$52.43M | -$35.76M | -$6.38M | -$9.82M | -$32.98M |
| Capital expenditure | $562,000 | $159,000 | $995,000 | $1.02M | $913,000 |
| Free cash flow | -$52.99M | -$35.92M | -$7.38M | -$10.84M | -$33.89M |
| Investing cash flow | -$562,000 | -$159,000 | -$995,000 | -$2.52M | -$913,000 |
| Financing cash flow | $102.62M | $83.59M | $3.97M | $11.59M | $30.11M |
| Depreciation & amortization | $548,000 | $718,000 | $1.34M | $2.39M | $2.96M |
| Stock-based compensation | $7.62M | $7.10M | $2.69M | $4.38M | $6.82M |
Free plan shows the latest 5 periods; Pro shows all 9 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.